CompanyGraph
Santhera Pharmaceuticals Holding AG
SANN · SIX Swiss · Switzerland
santhera.comFinancials as of FY2025
At a glance
- Depends onUpstream position: supplies 6 industries, depends on 3
Sign in to view price data.
Sign inThe reported statements, read against the company's own industry.
Financials view
Market Capitalization
235.45MCHF285.85M · vs all stocks (USD)
Revenue (TTM)
77.19MCHF93.71M · vs all stocks (USD)
Profit Margin
-63.79%vs Biotechnology peers
Beta
-0.2730xvs all stocks
52-Week Change
41.39%vs all stocks
Market Capitalization
235.45MCHF285.85M · vs all stocks (USD)
Enterprise Value
238.40MCHF289.43M · vs all stocks (USD)
Forward P/E
93.06xvs Biotechnology peers
Price to Sales (TTM)
3.13xvs Biotechnology peers
Enterprise to Revenue
3.09xvs Biotechnology peers
Enterprise to EBITDA
-7.33xvs Biotechnology peers
Gross Margin
86.34%vs Biotechnology peers
Profit Margin
-63.79%vs Biotechnology peers
Operating Margin
-4.08%vs Biotechnology peers
Return on Assets (TTM)
-15.64%vs Biotechnology peers
Revenue (TTM)
77.19MCHF93.71M · vs all stocks (USD)
Revenue per Share (TTM)
5.93CHFUpdated Sep 23, 2026Quarterly Revenue Growth
112.70%vs Biotechnology peers
Gross Profit (TTM)
15.17MCHF18.42M · vs all stocks (USD)
EBITDA (TTM)
-32.54MCHF-39.50M · vs all stocks (USD)
Net Income (TTM)
-49.24MCHF-59.78M · vs all stocks (USD)
Operating Cash Flow (TTM)
-34.76MCHF-42.20M · vs all stocks (USD)
Levered Free Cash Flow (TTM)
-35.63MCHF-43.26M · vs all stocks (USD)
Trailing Annual Dividend Rate
0.00CHFUpdated Sep 23, 2026Trailing Annual Dividend Yield
0.00%vs all stocks
Payout Ratio
0.00%vs Biotechnology peers
Revenue
77.19MCHFFY2025 · Dec 31, 2025Cost of Goods Sold
62.01MCHFFY2025 · Dec 31, 2025Gross Profit
15.17MCHFFY2025 · Dec 31, 2025Operating Income
-37.61MCHF-45.66M · vs all stocks (USD)
Pre-tax Income
-49.05MCHFFY2025 · Dec 31, 2025Income Tax Expense
185.00KCHFFY2025 · Dec 31, 2025Net Income
-49.24MCHFFY2025 · Dec 31, 2025EBIT
-37.49MCHFFY2025 · Dec 31, 2025EBITDA (Income Statement)
-35.05MCHFFY2025 · Dec 31, 2025Research & Development
22.22MCHFFY2025 · Dec 31, 2025Selling, General & Administrative
30.77MCHFFY2025 · Dec 31, 2025Non-operating Interest Income
409.00KCHFFY2025 · Dec 31, 2025Non-operating Interest Expense
11.56MCHFFY2025 · Dec 31, 2025EPS (Basic)
-3.78CHFFY2025 · Dec 31, 2025EPS (Diluted)
-3.78CHFFY2025 · Dec 31, 2025Basic Shares Outstanding
13.01MSharesFY2025 · Dec 31, 2025Diluted Shares Outstanding
13.01MSharesFY2025 · Dec 31, 2025Preferred Stock Dividends
0.00CHFFY2025 · Dec 31, 2025Operating Cash Flow
-34.91MCHFFY2025 · Dec 31, 2025Free Cash Flow
-34.96MCHFFY2025 · Dec 31, 2025Cash & Cash Equivalents (End of Period)
22.44MCHFFY2025 · Dec 31, 2025Starting Profit (CF Statement)
-49.05MCHFFY2025 · Dec 31, 2025Stock-based Compensation
4.25MCHFFY2025 · Dec 31, 2025Other Non-cash Items
11.21MCHFFY2025 · Dec 31, 2025Change in Other Assets/Liabilities
-1.31MCHFFY2025 · Dec 31, 2025Capital Expenditures
-52.00KCHFFY2025 · Dec 31, 2025Purchase of Investments
-70.00KCHFFY2025 · Dec 31, 2025Sale of Investments
0.00CHFFY2025 · Dec 31, 2025Net Investing Cash Flow
-122.00KCHFFY2025 · Dec 31, 2025Long-term Debt Issuance
9.69MCHFFY2025 · Dec 31, 2025Long-term Debt Payments
0.00CHFFY2025 · Dec 31, 2025Other Financing Charges
6.86MCHFFY2025 · Dec 31, 2025Net Financing Cash Flow
17.21MCHFFY2025 · Dec 31, 2025Shares Outstanding
13.39MSharesUpdated Sep 23, 2026Float Shares
11.28MSharesUpdated Sep 23, 2026% Held by Insiders
14.50%vs all stocks
% Held by Institutions
14.00%vs all stocks
Total Cash (MRQ)
22.44MCHF27.24M · vs all stocks (USD)
Total Cash per Share (MRQ)
1.68CHFUpdated Sep 23, 2026Total Debt (MRQ)
48.95MCHF59.43M · vs all stocks (USD)
Current Ratio (MRQ)
1.29xvs Biotechnology peers
Book Value per Share (MRQ)
-0.8820CHFUpdated Sep 23, 2026Total Assets
148.09MCHF179.79M · vs all stocks (USD)
Total Current Assets
80.24MCHFFY2025 · Dec 31, 2025Total Liabilities
159.90MCHFFY2025 · Dec 31, 2025Total Non-current Assets
67.84MCHFFY2025 · Dec 31, 2025Total Non-current Liabilities
97.73MCHFFY2025 · Dec 31, 2025Total Current Liabilities
62.17MCHFFY2025 · Dec 31, 2025Cash
22.44MCHFFY2025 · Dec 31, 2025Cash Equivalents
0.00CHFFY2025 · Dec 31, 2025Cash & Cash Equivalents
22.44MCHFFY2025 · Dec 31, 2025Accounts Receivable
8.70MCHFFY2025 · Dec 31, 2025Inventory
24.87MCHFFY2025 · Dec 31, 2025Accounts Payable
13.58MCHFFY2025 · Dec 31, 2025Short-term Debt
14.85MCHFFY2025 · Dec 31, 2025Other Current Liabilities
7.15MCHFFY2025 · Dec 31, 2025Long-term Debt
34.10MCHFFY2025 · Dec 31, 2025Other Non-current Liabilities
39.93MCHFFY2025 · Dec 31, 2025Common Stock (Book)
1.40MCHFFY2025 · Dec 31, 2025Retained Earnings
-663.93MCHFFY2025 · Dec 31, 2025Total Shareholders' Equity
-11.82MCHF-14.35M · vs all stocks (USD)
Treasury Stock
62.00KCHFFY2025 · Dec 31, 202552-Week Low
9.38CHFUpdated Sep 23, 202652-Week High
18.84CHFUpdated Sep 23, 202652-Week Change
41.39%vs all stocks
Beta
-0.2730xvs all stocks
50-Day MA
15.53CHFUpdated Sep 23, 2026200-Day MA
15.26CHFUpdated Sep 23, 2026Avg 10-Day Volume
51.60KSharesUpdated Sep 23, 2026Avg 30-Day Volume
67.29KSharesUpdated Sep 23, 2026Diluted EPS (TTM)
-3.78CHFUpdated Sep 23, 2026Shared structure with peers — never a ranking.
Relationships view
Structural observations derived from financial data, industry benchmarks, and supply chain position.
Structural Tensions
High gross margins eroded by operating costsNotable
Gross Margin: 0.86Profit Margin: -0.64
Supply Chain
Upstream position: supplies 6 industries, depends on 3Notable
Outgoing: 6.00Incoming: 3.00
Companies that share the same coordination system — how they create, deliver, or capture value.
Fulcrum Therapeutics Inc.
Tier 1ProductionApproval-Gated PipelineRule
Dirui Industrial Co., Ltd.
Tier 1ProductionApproval-Gated PipelineRule
Rocket Pharmaceuticals Inc.
Tier 1ProductionApproval-Gated PipelineRule
Inhibikase Therapeutics Inc.
Tier 1ProductionApproval-Gated PipelineRuleRisk
Perspective Therapeutics Inc.
Tier 1ProductionApproval-Gated PipelineRuleSenseMaking
Inventage Lab Inc.
Tier 1ProductionApproval-Gated PipelineRule
Abclon Inc.
Tier 1ProductionApproval-Gated PipelineRuleRisk
Standard Biotools Inc.
Tier 1ProductionApproval-Gated PipelineRule
Upstream Bio, Inc.
Tier 1ProductionApproval-Gated PipelineRuleRisk
Cutia Therapeutics Limited
Tier 1ProductionApproval-Gated PipelineRuleRisk